Physician profile
Nardine Smoak
NPI 1295362903
$868.27
in general payments reported to CMS, 2019-2025
16 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.62 · 2023: $254 · 2024: $277 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.08 |
| Education | $238.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.33 | 2024-2025 | |
| Abbott Laboratories | $238.57 | 2023 | Ensite |
| Novo Nordisk INC | $68.02 | 2023-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $49.15 | 2024-2025 | Vyepti |
| Pfizer INC. | $46.37 | 2024 | |
| Lilly USA, LLC | $28.33 | 2024-2025 | Mounjaro, Zepbound |
| Argenx US, INC. | $28.08 | 2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $21.08 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $19.61 | 2024 | Onpattro |
| Genentech USA, INC. | $18.41 | 2024 | Ocrevus, Ocrevus Zunovo |
| Tris Pharma INC | $18.02 | 2024 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $16.75 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $14.76 | 2025 | |
| Cardiva Medical, INC. | $14.62 | 2021 | |
| Exact Sciences Corporation | $13.96 | 2025 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.21 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nardine Smoak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.